Octreotide Long-Acting Repeatable Use Among Elderly Patients With Carcinoid Syndrome and Survival Outcomes

奥曲肽可重复长效治疗老年患者癌综合症和预后

BACKGROUND: Octreotide long-acting repeatable (LAR) is indicated for the treatment of carcinoid syndrome and diarrhea related to VIPoma, and may delay tumor growth in patients with neuroendocrine tumors (NETs). To the authors’ knowledge, the pattern of octreotide LAR use in clinical practice and its impact on survival outcomes has not been well documented. METHODS: Using the Sur-veillance, Epidemiology, and End Results (SEER)-Medicare database, the authors identified patients with NET aged?65 years who were diagnosed between July 1999 and December 2007. Patients with US Food and Drug Administration-approved indications for octreotide LAR were identified from Medicare claims. Multivariate logistic regression was performed to ascertain factors associated with octreotide LAR use, whereas the Cox proportional hazards model was used to evaluate the impact of octreotide LAR on survival.

RESULTS: Among those with Food and Drug Administration-approved indications, 245 of 4848 patients with distant-stage disease (51%) and 81 of 807 patients with local/regional disease (10%) initiated treatment with octreotide LAR within 6 months of diagnosis. Multivariate logistic regression indicated that among those with distant-stage disease, older age (? 80 years vs 65-69 years) (odds ratio [OR], 0.43; 95% confidence interval [95% CI], 0.23-0.81), female sex (OR, 0.62; 95% CI, 0.40-0.97), and living in the South (vs Northeast) (OR, 0.36; 95% CI, 0.18-0.72) were associated with a lower likelihood of using octreotide LAR. The multivariate propor-tional hazards model showed that octreotide LAR provided a significant 5-year survival benefit for patients with distant-stage disease (hazards ratio, 0.61; P?.001), whereas this survival benefit was not shown for the patients with local/regional stage (hazards ratio, 0.88; P5.563). CONCLUSIONS: The results of this retrospective study suggest a possible survival benefit for the use of octreotide LAR in elderly patients with distant-stage NET with carcinoid syndrome. The results of the current study also suggest that octreotide
LAR is underused in this population despite recommended guidelines. Cancer 2014;000:000–000. VC 2014 American Cancer Society.

KEYWORDS: neuroendocrine tumors, malignant carcinoid syndrome, somatostatin analog, octreotide, health services for the aged, Surveillance, Epidemiology, and End Results (SEER)-Medicare.